Therapeutic efficacy and safety of bicizumab

Bimekizumab (Bimekizumab) is a new generation of IL-17A and IL-17F dual-targeting humanized monoclonal antibody. It is used to treat a variety of immune-mediated diseases. It is mainly used for The disease is moderate to severe plaque psoriasis (Psoriasis), and it also shows potential advantages in the treatment of psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Its innovative dual-target mechanism makes it stand out among many biological agents of the IL-17 pathway, showing excellent clinical value in improving skin lesions, relieving joint pain, and improving quality of life.

From the perspective of therapeutic effect, bichizumab can significantly inhibit the inflammatory response, quickly reduce psoriatic skin lesions, and achieve a high level of PASI score improvement in a short period of time.PASI score improvement. Compared with other IL-17A single-targeting drugs, such as Secukinumab and Ixekizumab, Bicizumab inhibits IL-17A and IL-17F at the same time, thus having a wider range of inflammation control, higher efficiency, and faster onset of action. The drug provides a more stable and powerful alternative for patients who have long-term relapses and are ineffective or intolerant to traditional treatments.

In terms of safety, bicizumab was generally well tolerated and the incidence of adverse reactions was relatively low. The most common adverse events are upper respiratory tract infection, oral candida infection and injection site reaction, most of which are mild to moderate and usually do not require interruption of treatment. Since this drug may have a certain impact on mucosal-associated flora, attention should be paid to the risk of candida infection during use, especially in patients with underlying immune problems or a history of diabetes, who should be monitored regularly.

Bicizumab is administered by subcutaneous injection. In the initial period, high-frequency administration is usually carried out within the first few weeks. Subsequently, it can be injected once a month or every two months in the maintenance phase, which significantly improves the patient's treatment compliance and life convenience. In most cases, patients' skin regained smoothness, itching symptoms were significantly reduced, and long-term relief was even maintained after using the drug.

Reference materials:https://www.drugs.com/bimekizumab.html